AMPLIA THERAPEUTICS ORD
Amplia Therapeutics Releases New Topline Data from ACCENT Narmafotinib Pancreatic Cancer Trial
Amplia Therapeutics (ASX: ATX) has released new topline data from an ongoing trial of its best-in-class selective FAK inhibitor narmafotinib on advanced pancreatic cancer. The ACCENT clinical trial is investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of narmafotinib when used in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Latest data to 20 July has […]
Amplia Therapeutics achieves second complete response with narmafotinib in pancreatic cancer trial
Amplia Therapeutics (ASX: ATX) continues to make excellent progress with focal adhesion kinase (FAK) inhibitor narmafotinib, its best-in-class drug candidate for pancreatic cancer. New data from the company’s ongoing ACCENT trial investigating narmafotinib has further confirmed its potential. After Amplia’s announcement earlier this week that a separate patient had achieved a pathological complete response (CR) […]
Amplia Therapeutics reports first pathological complete response in ACCENT pancreatic cancer trial
Amplia Therapeutics (ASX: ATX) has recorded the first pathological complete response (pCR) from a patient participating in the company’s ongoing ACCENT clinical trial to treat metastatic pancreatic cancer. The trial is investigating the company’s best-in-class FAK (focal adhesion kinase) inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. The patient recorded a pCR after […]
Amplia Therapeutics allocated FDA fast-tracking for pancreatic cancer drug narmafotinib
Melbourne-based Amplia Therapeutics (ASX: ATX) has been granted Fast Track Designation for its narmafotinib advanced pancreatic cancer treatment candidate by the US Food and Drug Administration (FDA). Narmafotinib is the company’s best-in-class inhibitor of the focal adhesion kinase protein (FAK), which is over-expressed in pancreatic and other cancers and a drug target gaining increasing attention […]